Summit Therapeutics plc : Holding(s) in Company


TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: SUMMIT THERAPEUTICS PLC
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer  
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)iii:  
3. Details of person subject to the notification obligationiv
Name CANACCORD GENUITY GROUP INC
City and country of registered office (if applicable) VANCOUVER, CANADA
4. Full name of shareholder(s) (if different from 3.)v
Name DISCRETIONARY CLIENTS
City and country of registered office (if applicable) As above
5. Date on which the threshold was crossed or reachedvi: 27 JUNE 2018
6. Date on which issuer notified (DD/MM/YYYY): 02 JULY 2018
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached 4.4621   4.4621 81,989,004
Position of previous notification (if
applicable)
6.7647   6.7647  


8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01 N/A 3,658,400 N/A 4.4621
         
         

SUBTOTAL 8. A 3,658,400 4.4621
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
         
         
         
    SUBTOTAL 8. B 1    
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
           
           
           
      SUBTOTAL 8.B.2    
 

 
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Canaccord Genuity Group Inc. 4.4621   4.4621
Canaccord Genuity Wealth Group Holdings Limited 4.4621   4.4621
Canaccord Genuity Wealth Group Holdings (Jersey) Limited 4.4621   4.4621
Hargreave Hale Ltd 4.4621   4.4621
 
10. In case of proxy voting, please identify:
Name of the proxy holder  
The number and % of voting rights held  
The date until which the voting rights will be held  
 
11. Additional informationxvi
 

Place of completion BLACKPOOL, ENGLAND
Date of completion 02 JULY 2018